1.1. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-40.2.2. O'Leary DH, Polak JF, Kronmal RA. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.3.3. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96 (5):1432-7.4.4. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.5.5. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.6.6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351 (9118): 1755-62.7.7. Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157-72.8.8. Zhang Y, Zhang X, Liu L et al. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011; 32 (12): 1500-8.9.9. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27.10.10. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.11.11. De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-5.12.12. Nalbantgil I, Onder R, Killiçcioglu B et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press 1996; 5 (5): 285-91.13.13. Wetzchewald D, Klaus D, Garanin G et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment--a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992; 231 (3): 303-8.14.14. Zanchetti A, Bold G, Hennig M et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.15.15. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J A M A 2004; 292 (18): 2217-25.16.16. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 2005; 360 (1464): 2259-72.17.17. Song H, Bao W, Wang H et al. Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension. Clin Chem Lab Med 2008; 46 (3): 393-5.18.18. Xing SS, Tan HW, Bi XP et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med 2008; 14 (7-8): 395-402.19.19. Bi XP, Tan HW, Xing SS et al. Felodipine downregulates srum interleukin-18 levels in rats with fructose-induced metabolic syndrome. J Endocrinol Invest 2009; 32 (4): 303-7.20.20. Amenta F, Lanari A, Mignini F et al. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci 2009; 283 (1-2): 219-23.21.21. Kimura Y, Kitagawa K, Oku N et al. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions. Hypertens Res 2008; 31 (12): 2147-54.22.22. Русина А.М., Мордовин В.Ф., Федоренко Е.В. и др. Сравнительный анализ гипотензивной и церебропротективной эффективности антагонистов кальция и b-блокаторов у пациентов с гипертонической болезнью и хронической гипертензивной энцефалопатией. РМЖ. 2009; 17 (1): 1-5.23.23. Lehri S, Grässel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000; 125 (45): 1350-5.24.24. Смоленская О.Г., Клейнер С.Л., Ставрова Н.Ю. Терапия гипертонической болезни блокаторами кальциевых каналов пролонгированного действия. Кардиология. 2004; 5: 59-62.25.25. Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005; 17 (Suppl. 4): 16-30.26.26. Dworkin LD, Benstein JA, Parker M et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-14.27.27. Harris DCH, Hammond WS, Burke TJ. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41-6.28.28. Dworkin LD, Tolbert E, Recht PA. Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 1996; 27: 245-50.29.29. Brunner FP, Bock HA, Hermle M. Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 1991; 6: 420-7.30.30. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by сalcium‐channel blockers. Nephrol Dial Transplant 1997; 12: 2244-50.31.31. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy:an updated meta-analysis. Nephrol Dial Transplant 1995; (Suppl. 10): 39-45.32.32. Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.33.33. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood‐pressure‐lowering agents: a meta‐analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.34.34. Mene P. Calcium channel blockers: what they can and what they can\'t do. Nephrol Dial Transplant 1997; 12 (1): 25-8.35.35. Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16 (11): 2158-65.36.36. Callera GE, Montezano AC, Yogi A et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-8.37.37. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10 (2): 97-107.38.38. Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003; 5 (1): 59-65.39.39. Dietz JD, Du S, Bolten CW et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-8.40.40. Matsubara BB, Franco M, Janicki JS et al. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Braz J Med Biol Res 2010; 43 (5): 506-14.41.41. Schaefer RM, Aldons PM, Burgess ED et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomized, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998; 52 (6): 381-6.42.42. Bicchi M, Vedovini G, Cappelli R et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373-80.43.43. Агеев Ф.Т., Фофанова Т.В., Деев А.Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных с артериальной гипертонией. Кардиология. 2009; 1: 30-3.